Ataluren (PTC124®) + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Cystic Fibrosis
Conditions
Cystic Fibrosis
Trial Timeline
Aug 1, 2014 → Nov 1, 2016
NCT ID
NCT02139306About Ataluren (PTC124®) + Placebo
Ataluren (PTC124®) + Placebo is a phase 3 stage product being developed by PTC Therapeutics for Cystic Fibrosis. The current trial status is completed. This product is registered under clinical trial identifier NCT02139306. Target conditions include Cystic Fibrosis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02139306 | Phase 3 | Completed |
Competing Products
20 competing products in Cystic Fibrosis